China Tocilizumab Market Investigation Report 2021-2025


DUBLIN, July 20, 2021– (COMMERCIAL THREAD)–The “Chinese Tocilizumab Market Investigation Report 2021-2025” the report was added to offer.

The trade name of Tocilizumab is ACTEMRA, which was developed by Roche Pharma (Switzerland) AG. In 2013, its product was first approved in China and its indication is RA.

Tocilizumab was approved in China as the first biologic for the treatment of JIA in 2016, was included in Chinese medical insurance in 2019, and was approved in China for the third indication for CRS in 2020. D ‘By 2020, tocilizumab has registered a number of studies in China, and its indications include RA, JIA, and CRS. By 2020, Roche Pharma (Switzerland) AG is the sole manufacturer in the Chinese market of tocilizumab.

Market research shows that Tocilizumab sales have trended upward from 2016 to 2020. Since Tocilizumab was approved for the new sAJI indication in 2016, sales increased in 2017 to 21.30% of growth rate from 2016 to 2017. With the inclusion of Tocilizumab in Chinese medical insurance in 2019 and the approval of its new indications in China in 2020, sales in 2020 have clearly increased to 20.07 million CNY in 2019 to CNY 41.72 million in 2020. The growth rate is about 107.89%. The Tocilizumab CAGR was 16.25% from 2016 to 2020.

According to the market research, as the tocilizumab market expands from 2021 to 2025, its sales will continue to grow. The patent for the original tocilizumab injection has expired, but no biosimilar drug has been approved in China. Currently, five pharmaceutical companies are conducting relevant clinical trials. After the approval of tocilizumab biosimilars on the market, its manufacturers will gradually increase, the market will continue to grow, and the price will decline.

These situations will lead to increased sales value and sales volume of Tocilizumab. Additionally, tocilizumab has been approved for 5 indications in other countries and China has approved 3 indications, so the number of indications approved in China has the potential to increase. It can be predicted that with increasing indications, its sales will continue to grow as the market expands in the future.

Topics covered:

  • The impact of COVID-19 on the Chinese tocilizumab market

  • Chinese tocilizumab sales value 2016-2020

  • Competitive landscape of the Chinese tocilizumab market

  • Price of tocilizumab in China

  • China Tocilizumab Price by Regions and Manufacturers

  • Analysis of factors affecting the development of the Chinese tocilizumab market

  • China tocilizumab market outlook from 2021 to 2025

Main topics covered:

1 Relevant concept of tocilizumab

1.1 Indications for tocilizumab

1.2 Development of Tocilizumab in China

1.3 Government approval of tocilizumab in China

1.4 The impact of COVID-19 on tocilizumab sales in China

2 Tocilizumab sales in China, 2016-2020

2.1 Sales value of tocilizumab

2.1.1 Overall value of sales

2.1.2 Sales Value by Regions

2.2 Tocilizumab Sales Volume

2.2.1 Global sales volume

2.2.2 Sales Volume by Regions

2.3 China Sales of Tocilizumab by Dosage Form, 2016-2020

2.3.1 Injection

2.3.2 Analysis of other dosage forms

3 China Top Manufacturers Analysis of Tocilizumab, 2016-2020

3.1 Major Manufacturers of Tocilizumab Market Share Analysis

3.1.1 Market Share by Sales Value Survey

3.1.2 Market Share by Sales Volume Survey

3.2 Roche Pharma (Suisse) SA

3.2.1 Company profile

3.2.2 Sales of ACTEMRA (Tocilizumab by Roche Pharma (Schweiz) AG) in China

4 Tocilizumab Price for Different Manufacturers in China, 2020-2021

4.1 Roche Pharma (Switzerland) AG (ACTEMRA)

4.2 Others

5 China Tocilizumab Market Outlook, 2021-2025

5.1 Factors influencing the development of the Chinese tocilizumab market

5.1.1 The impact of COVID-19 on the Chinese tocilizumab market

5.1.2 Market Drivers and Opportunities

5.1.3 Market threats and challenges

5.2 Market Size Forecast

5.3 Market Trend Forecast

Companies mentioned

For more information on this report, visit

See the source version on

Laura Wood, Senior Press Director
[email protected]

For EST office hours, call 1-917-300-0470
For USA / CAN call toll free 1-800-526-8630
For GMT office hours, call + 353-1-416-8900


Comments are closed.